# Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 8.2 | 122.3 | (58.5-224.9) |  | Male | 17 | 5.3 | 318.8 | (185.6-510.4) |
| Female | 3 | 3.1 | nc | (nc-nc) |  | Female | 4 | 4.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 1.5 | nc | (nc-nc) |  | Male | 3 | 1.8 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 4 | 4.7 | nc | (nc-nc) |
| Female | 37 | 37.9 | 97.5 | (68.7-134.4) |  | Female | 6 | 4.4 | 137.9 | (50.3-300.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 4.2 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 8.6 | 127.4 | (63.5-228.0) |  |  |  |  |  |  |
| Female | 2 | 8.3 | nc | (nc-nc) |  | Female | 4 | 3.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 3 | 3.2 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 1 | 3.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 41 | 27.7 | 148.2 | (106.3-201.1) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 5.0 | nc | (nc-nc) |  | Male | 0 | 2.0 | nc | (nc-nc) |
| Female | 5 | 3.0 | 169.0 | (54.5-394.3) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 3.2 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 7 | 6.7 | 105.1 | (42.1-216.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 12 | 9.2 | 131.0 | (67.6-228.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 15.0 | 73.6 | (36.7-131.6) |  | Male | 123 | 108.7 | 113.1 | (94.0-135.0) |
| Female | 10 | 17.2 | 58.1 | (27.8-106.8) |  | Female | 104 | 121.4 | 85.7 | (70.0-103.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

214

# Newburyport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 21 | 21.3 | 98.8 | (61.1-151.0) |  | Male | 20 | 14.0 | 143.4 | (87.5-221.4) |
| Female | 5 | 8.9 | 56.0 | (18.0-130.7) |  | Female | 15 | 11.9 | 125.7 | (70.3-207.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 4.1 | nc | (nc-nc) |  | Male | 1 | 4.6 | nc | (nc-nc) |
| Female | 3 | 3.8 | nc | (nc-nc) |  | Female | 5 | 4.2 | 119.3 | (38.4-278.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 0.8 | nc | (nc-nc) |  | Male | 14 | 12.4 | 113.3 | (61.9-190.1) |
| Female | 96 | 99.6 | 96.4 | (78.1-117.7) |  | Female | 9 | 12.1 | 74.2 | (33.8-140.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 11.1 | 81.1 | (37.0-154.0) |
| Female | 0 | 3.0 | nc | (nc-nc) |  | Female | 6 | 5.5 | 110.1 | (40.2-239.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 25 | 22.9 | 109.1 | (70.6-161.1) |  |  |  |  |  |  |
| Female | 21 | 24.9 | 84.4 | (52.2-129.0) |  | Female | 3 | 8.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 5.7 | nc | (nc-nc) |  | Male | 9 | 8.2 | 110.0 | (50.2-208.9) |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 8 | 9.3 | 86.2 | (37.1-169.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 90 | 72.0 | 125.0 | (100.5-153.6) |
| Female | 2 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 13.2 | 45.4 | (16.6-98.9) |  | Male | 4 | 5.1 | nc | (nc-nc) |
| Female | 3 | 8.0 | nc | (nc-nc) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.4 | nc | (nc-nc) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 8.5 | 129.2 | (64.4-231.2) |  | Male | 12 | 5.7 | 212.2 | (109.5-370.7) |
| Female | 1 | 6.9 | nc | (nc-nc) |  | Female | 21 | 16.7 | 126.0 | (78.0-192.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 8.2 | 60.7 | (19.6-141.6) |  |  |  |  |  |  |
| Female | 3 | 3.0 | nc | (nc-nc) |  | Female | 26 | 23.6 | 110.3 | (72.1-161.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 25 | 38.2 | 65.4 | (42.3-96.5) |  | Male | 282 | 284.3 | 99.2 | (87.9-111.5) |
| Female | 36 | 47.5 | 75.8 | (53.1-104.9) |  | Female | 295 | 331.1 | 89.1 | (79.2-99.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

215

# Newton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 111 | 102.0 | 108.8 | (89.5-131.0) |  | Male | 68 | 63.4 | 107.2 | (83.3-135.9) |
| Female | 46 | 35.6 | 129.1 | (94.5-172.2) |  | Female | 68 | 49.4 | 137.8 | (107.0-174.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 22 | 18.3 | 120.3 | (75.4-182.2) |  | Male | 28 | 20.5 | 136.3 | (90.5-197.0) |
| Female | 18 | 16.3 | 110.2 | (65.3-174.2) |  | Female | 16 | 16.7 | 96.1 | (54.9-156.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 64 | 56.3 | 113.6 | (87.5-145.1) |
| Female | 447 | 399.4 | 111.9 | (101.8-122.8) |  | Female | 54 | 48.9 | 110.4 | (82.9-144.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 28 | 45.7 | 61.3 | (40.7-88.6) |
| Female | 8 | 13.0 | 61.7 | (26.6-121.5) |  | Female | 29 | 21.8 | 133.1 | (89.1-191.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 100 | 103.9 | 96.2 | (78.3-117.0) |  |  |  |  |  |  |
| Female | 82 | 102.1 | 80.3 | (63.9-99.7) |  | Female | 47 | 34.3 | 136.9 | (100.6-182.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 25.1 | 35.9 | (16.4-68.1) |  | Male | 30 | 37.1 | 80.8 | (54.5-115.3) |
| Female | 6 | 7.0 | 85.5 | (31.2-186.0) |  | Female | 51 | 37.4 | 136.3 | (101.5-179.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 10 | 6.6 | 151.3 | (72.4-278.2) |  | Male | 332 | 294.3 | 112.8 | (101.0-125.6) |
| Female | 8 | 5.9 | 135.1 | (58.2-266.2) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 51 | 56.0 | 91.1 | (67.8-119.8) |  | Male | 25 | 23.5 | 106.3 | (68.8-156.9) |
| Female | 27 | 31.8 | 84.8 | (55.9-123.4) |  | Female | 11 | 14.4 | 76.5 | (38.1-136.9) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 9 | 14.5 | 62.1 | (28.3-117.9) |  | Male | 13 | 11.8 | 110.4 | (58.7-188.9) |
| Female | 0 | 4.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 34 | 40.0 | 85.0 | (58.9-118.8) |  | Male | 32 | 24.0 | 133.5 | (91.3-188.5) |
| Female | 27 | 29.0 | 93.0 | (61.3-135.3) |  | Female | 84 | 72.4 | 116.0 | (92.5-143.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 22 | 34.2 | 64.3 | (40.3-97.3) |  |  |  |  |  |  |
| Female | 9 | 11.9 | 75.5 | (34.4-143.2) |  | Female | 87 | 91.1 | 95.5 | (76.5-117.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 113 | 176.1 | 64.2 | (52.9-77.1) |  | Male | 1175 | 1258.9 | 93.3 | (88.1-98.8) |
| Female | 148 | 185.6 | 79.7 | (67.4-93.7) |  | Female | 1380 | 1336.2 | 103.3 | (97.9-108.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

216

# Norfolk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 13.2 | 60.8 | (26.2-119.8) |  | Male | 24 | 9.4 | 255.4 | (163.6-380.0) |
| Female | 1 | 2.8 | nc | (nc-nc) |  | Female | 4 | 4.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 6 | 8.3 | 72.4 | (26.5-157.7) |
| Female | 41 | 39.1 | 105.0 | (75.3-142.4) |  | Female | 2 | 4.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 7.7 | 77.4 | (28.3-168.6) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 15.1 | 59.6 | (27.2-113.1) |  |  |  |  |  |  |
| Female | 6 | 8.4 | 71.8 | (26.2-156.3) |  | Female | 1 | 3.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 3.8 | 131.6 | (42.4-307.2) |  | Male | 2 | 5.3 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 38 | 47.6 | 79.8 | (56.5-109.5) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 9.1 | 131.3 | (67.8-229.4) |  | Male | 5 | 3.3 | 150.2 | (48.4-350.5) |
| Female | 4 | 2.9 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  | Male | 0 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 5.7 | 87.8 | (28.3-204.9) |  | Male | 2 | 4.4 | nc | (nc-nc) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 10 | 7.7 | 129.9 | (62.2-239.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 5.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 7 | 9.1 | 76.9 | (30.8-158.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 16 | 24.4 | 65.7 | (37.5-106.6) |  | Male | 155 | 189.1 | 82.0 | (69.6-95.9) |
| Female | 13 | 15.2 | 85.4 | (45.4-146.1) |  | Female | 105 | 121.3 | 86.6 | (70.8-104.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

217

# North Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 16.6 | 114.5 | (68.9-178.8) |  | Male | 4 | 10.3 | nc | (nc-nc) |
| Female | 10 | 6.3 | 159.8 | (76.5-293.9) |  | Female | 6 | 8.0 | 74.9 | (27.4-163.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  | Male | 4 | 3.3 | nc | (nc-nc) |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 1 | 2.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 10 | 9.1 | 110.5 | (52.9-203.2) |
| Female | 50 | 63.9 | 78.2 | (58.0-103.1) |  | Female | 7 | 8.2 | 85.3 | (34.2-175.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 7.3 | 137.0 | (65.6-251.9) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 6 | 3.6 | 166.5 | (60.8-362.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 24 | 16.6 | 144.4 | (92.5-214.9) |  |  |  |  |  |  |
| Female | 17 | 17.6 | 96.4 | (56.1-154.4) |  | Female | 7 | 5.6 | 125.1 | (50.1-257.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 4.0 | 172.9 | (69.3-356.2) |  | Male | 0 | 6.0 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 7 | 6.6 | 106.0 | (42.5-218.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 38 | 47.2 | 80.4 | (56.9-110.4) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 9.0 | 78.1 | (31.3-160.9) |  | Male | 5 | 3.8 | 131.6 | (42.4-307.2) |
| Female | 3 | 5.2 | nc | (nc-nc) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 3 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 6.4 | 77.6 | (25.0-181.1) |  | Male | 6 | 3.8 | 157.6 | (57.5-343.0) |
| Female | 3 | 4.9 | nc | (nc-nc) |  | Female | 11 | 10.9 | 100.7 | (50.2-180.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 5.6 | 179.6 | (86.0-330.3) |  |  |  |  |  |  |
| Female | 3 | 2.0 | nc | (nc-nc) |  | Female | 12 | 14.5 | 83.0 | (42.8-145.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 28 | 29.0 | 96.7 | (64.2-139.8) |  | Male | 203 | 203.2 | 99.9 | (86.6-114.6) |
| Female | 41 | 32.1 | 127.8 | (91.7-173.4) |  | Female | 209 | 220.9 | 94.6 | (82.2-108.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

218

# North Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 32 | 28.8 | 111.2 | (76.1-157.0) |  | Male | 20 | 18.9 | 105.8 | (64.6-163.4) |
| Female | 6 | 11.4 | 52.6 | (19.2-114.5) |  | Female | 15 | 16.2 | 92.4 | (51.7-152.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 5.8 | 103.8 | (37.9-225.9) |  | Male | 6 | 6.0 | 100.3 | (36.6-218.2) |
| Female | 6 | 5.2 | 115.5 | (42.2-251.3) |  | Female | 8 | 5.4 | 149.1 | (64.2-293.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 20 | 16.8 | 118.8 | (72.5-183.4) |
| Female | 128 | 131.1 | 97.6 | (81.5-116.1) |  | Female | 14 | 15.8 | 88.5 | (48.4-148.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 14.5 | 76.0 | (37.9-136.0) |
| Female | 3 | 4.4 | nc | (nc-nc) |  | Female | 1 | 7.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 24 | 31.6 | 76.0 | (48.7-113.0) |  |  |  |  |  |  |
| Female | 37 | 33.7 | 109.7 | (77.2-151.2) |  | Female | 11 | 11.2 | 98.2 | (49.0-175.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 7.3 | 108.9 | (46.9-214.7) |  | Male | 6 | 10.8 | 55.5 | (20.3-120.8) |
| Female | 0 | 2.2 | nc | (nc-nc) |  | Female | 12 | 12.0 | 99.7 | (51.5-174.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 90 | 87.7 | 102.6 | (82.5-126.1) |
| Female | 5 | 1.9 | 266.4 | (85.8-621.6) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 17.3 | 69.5 | (35.9-121.5) |  | Male | 5 | 6.9 | 72.7 | (23.4-169.7) |
| Female | 7 | 10.3 | 67.8 | (27.2-139.8) |  | Female | 7 | 4.7 | 148.9 | (59.6-306.8) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 4.3 | nc | (nc-nc) |  | Male | 5 | 4.3 | 116.5 | (37.5-271.9) |
| Female | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 14 | 12.0 | 116.8 | (63.8-195.9) |  | Male | 12 | 8.1 | 148.8 | (76.8-259.9) |
| Female | 11 | 9.3 | 117.9 | (58.8-210.9) |  | Female | 22 | 24.5 | 89.6 | (56.2-135.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 10.5 | 56.9 | (20.8-123.8) |  |  |  |  |  |  |
| Female | 3 | 3.8 | nc | (nc-nc) |  | Female | 25 | 29.0 | 86.2 | (55.8-127.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 37 | 49.2 | 75.1 | (52.9-103.6) |  | Male | 351 | 374.1 | 93.8 | (84.3-104.2) |
| Female | 49 | 59.1 | 82.9 | (61.3-109.6) |  | Female | 397 | 434.7 | 91.3 | (82.6-100.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

219

# North Attleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 28 | 22.6 | 124.0 | (82.4-179.2) |  | Male | 15 | 16.3 | 91.8 | (51.3-151.4) |
| Female | 8 | 9.1 | 87.9 | (37.8-173.2) |  | Female | 20 | 14.3 | 139.4 | (85.1-215.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 5.3 | 112.5 | (41.1-245.0) |  | Male | 8 | 5.2 | 154.7 | (66.6-304.7) |
| Female | 6 | 4.7 | 127.6 | (46.6-277.8) |  | Female | 6 | 4.4 | 136.8 | (50.0-297.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 16 | 14.5 | 110.4 | (63.1-179.3) |
| Female | 117 | 116.3 | 100.6 | (83.2-120.5) |  | Female | 16 | 13.2 | 121.1 | (69.1-196.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 14 | 13.3 | 105.5 | (57.6-177.0) |
| Female | 0 | 4.2 | nc | (nc-nc) |  | Female | 3 | 6.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 31 | 26.4 | 117.2 | (79.6-166.4) |  |  |  |  |  |  |
| Female | 22 | 27.4 | 80.3 | (50.3-121.6) |  | Female | 4 | 9.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 6.4 | 140.7 | (64.2-267.0) |  | Male | 11 | 9.0 | 122.0 | (60.8-218.4) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 11 | 9.5 | 115.5 | (57.6-206.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 79 | 78.8 | 100.2 | (79.3-124.9) |
| Female | 1 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 15.9 | 75.6 | (39.0-132.0) |  | Male | 3 | 5.7 | nc | (nc-nc) |
| Female | 9 | 8.9 | 100.8 | (46.0-191.3) |  | Female | 4 | 3.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.8 | nc | (nc-nc) |  | Male | 5 | 4.5 | 110.1 | (35.5-257.0) |
| Female | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 10.1 | 49.3 | (15.9-115.0) |  | Male | 6 | 8.0 | 74.6 | (27.2-162.4) |
| Female | 4 | 7.9 | nc | (nc-nc) |  | Female | 25 | 23.8 | 105.2 | (68.0-155.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 9 | 9.3 | 96.4 | (44.0-183.0) |  |  |  |  |  |  |
| Female | 3 | 3.2 | nc | (nc-nc) |  | Female | 21 | 25.8 | 81.4 | (50.3-124.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 39 | 41.7 | 93.6 | (66.6-128.0) |  | Male | 334 | 324.4 | 103.0 | (92.2-114.6) |
| Female | 41 | 48.6 | 84.3 | (60.5-114.4) |  | Female | 350 | 374.5 | 93.5 | (83.9-103.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

220

# North Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 5.3 | nc | (nc-nc) |  | Male | 4 | 3.5 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 0 | 2.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 3.1 | nc | (nc-nc) |
| Female | 16 | 20.7 | 77.2 | (44.1-125.5) |  | Female | 4 | 2.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 5.6 | 106.2 | (38.8-231.2) |  |  |  |  |  |  |
| Female | 5 | 5.3 | 94.2 | (30.4-219.8) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 4 | 2.0 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 18 | 16.1 | 111.9 | (66.3-176.8) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.2 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 2 | 3.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 6 | 4.6 | 130.4 | (47.6-283.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 9.6 | 104.1 | (49.9-191.5) |  | Male | 71 | 69.0 | 102.9 | (80.4-129.8) |
| Female | 6 | 9.7 | 61.6 | (22.5-134.2) |  | Female | 63 | 69.2 | 91.0 | (69.9-116.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

221

# North Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 16.2 | 86.7 | (47.3-145.4) |  | Male | 11 | 10.8 | 101.5 | (50.6-181.7) |
| Female | 7 | 5.6 | 125.4 | (50.2-258.3) |  | Female | 9 | 8.5 | 105.8 | (48.3-200.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  | Male | 2 | 3.5 | nc | (nc-nc) |
| Female | 5 | 2.7 | 186.0 | (59.9-434.1) |  | Female | 1 | 2.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 10 | 9.6 | 104.2 | (49.9-191.6) |
| Female | 82 | 71.7 | 114.4 | (91.0-142.0) |  | Female | 4 | 8.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 8.4 | nc | (nc-nc) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 1 | 3.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 17.5 | 79.9 | (43.6-134.0) |  |  |  |  |  |  |
| Female | 14 | 16.4 | 85.3 | (46.6-143.2) |  | Female | 4 | 6.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 4.3 | 185.6 | (79.9-365.7) |  | Male | 6 | 6.2 | 97.1 | (35.4-211.3) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 7 | 5.7 | 122.3 | (49.0-252.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 50 | 52.1 | 95.9 | (71.2-126.4) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 10.1 | 98.9 | (47.4-182.0) |  | Male | 3 | 3.9 | nc | (nc-nc) |
| Female | 3 | 5.5 | nc | (nc-nc) |  | Female | 0 | 2.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 6.7 | 119.5 | (51.5-235.5) |  | Male | 6 | 4.6 | 129.7 | (47.4-282.3) |
| Female | 4 | 4.6 | nc | (nc-nc) |  | Female | 18 | 13.7 | 131.6 | (78.0-208.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 6.2 | 80.8 | (26.0-188.5) |  |  |  |  |  |  |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 18 | 16.2 | 111.0 | (65.7-175.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 15 | 29.2 | 51.4 | (28.8-84.8) |  | Male | 189 | 215.9 | 87.6 | (75.5-101.0) |
| Female | 24 | 30.8 | 78.0 | (50.0-116.1) |  | Female | 219 | 227.9 | 96.1 | (83.8-109.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

222

# Northampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 41 | 29.7 | 138.3 | (99.2-187.6) |  | Male | 13 | 18.8 | 69.3 | (36.9-118.5) |
| Female | 11 | 11.4 | 96.9 | (48.3-173.4) |  | Female | 9 | 15.9 | 56.7 | (25.9-107.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 5.5 | 108.5 | (39.6-236.1) |  | Male | 1 | 6.1 | nc | (nc-nc) |
| Female | 4 | 5.4 | nc | (nc-nc) |  | Female | 7 | 5.4 | 130.0 | (52.1-267.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 18 | 16.8 | 107.3 | (63.6-169.6) |
| Female | 166 | 127.3 | 130.4 | (111.3-151.8) |  | Female | 16 | 15.8 | 101.5 | (58.0-164.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 15 | 13.9 | 107.9 | (60.4-178.0) |
| Female | 5 | 4.0 | 123.9 | (39.9-289.2) |  | Female | 4 | 7.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 29 | 30.5 | 95.2 | (63.7-136.7) |  |  |  |  |  |  |
| Female | 37 | 32.5 | 113.7 | (80.0-156.7) |  | Female | 17 | 11.1 | 152.6 | (88.8-244.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 7.5 | 106.2 | (45.7-209.3) |  | Male | 10 | 11.0 | 91.1 | (43.6-167.5) |
| Female | 4 | 2.2 | nc | (nc-nc) |  | Female | 11 | 11.9 | 92.4 | (46.1-165.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 54 | 91.4 | 59.1 | (44.4-77.1) |
| Female | 1 | 2.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 16.9 | 71.1 | (36.7-124.1) |  | Male | 6 | 6.9 | 86.7 | (31.7-188.8) |
| Female | 9 | 10.2 | 88.4 | (40.4-167.9) |  | Female | 4 | 4.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 4.4 | nc | (nc-nc) |  | Male | 7 | 4.0 | 175.4 | (70.3-361.5) |
| Female | 3 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 11.8 | 110.5 | (58.8-188.9) |  | Male | 4 | 7.4 | nc | (nc-nc) |
| Female | 7 | 9.3 | 75.2 | (30.1-154.9) |  | Female | 10 | 23.3 | 42.9 | (20.6-79.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 10.5 | 47.7 | (15.4-111.3) |  |  |  |  |  |  |
| Female | 3 | 3.9 | nc | (nc-nc) |  | Female | 44 | 29.7 | 148.2 | (107.7-198.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 44 | 51.8 | 84.9 | (61.7-114.0) |  | Male | 314 | 377.7 | 83.1 | (74.2-92.9) |
| Female | 44 | 59.0 | 74.6 | (54.2-100.2) |  | Female | 454 | 428.0 | 106.1 | (96.5-116.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

223

# Northborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 21 | 16.2 | 129.5 | (80.2-198.0) |  | Male | 12 | 10.7 | 111.6 | (57.6-195.0) |
| Female | 7 | 5.8 | 121.1 | (48.5-249.4) |  | Female | 8 | 8.1 | 98.2 | (42.3-193.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 4 | 3.5 | nc | (nc-nc) |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 5 | 2.7 | 185.0 | (59.6-431.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 10 | 9.5 | 104.7 | (50.1-192.6) |
| Female | 73 | 66.0 | 110.6 | (86.7-139.0) |  | Female | 5 | 8.0 | 62.5 | (20.2-145.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 8.3 | 96.4 | (41.5-190.0) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 2 | 3.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 17.9 | 61.6 | (30.7-110.2) |  |  |  |  |  |  |
| Female | 15 | 16.8 | 89.3 | (49.9-147.2) |  | Female | 3 | 5.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 4.2 | 190.9 | (82.2-376.3) |  | Male | 6 | 6.2 | 97.4 | (35.6-212.1) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 6 | 6.0 | 99.5 | (36.3-216.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 50 | 50.3 | 99.5 | (73.8-131.1) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 10.0 | 100.4 | (48.0-184.6) |  | Male | 2 | 3.9 | nc | (nc-nc) |
| Female | 4 | 5.2 | nc | (nc-nc) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 2.5 | nc | (nc-nc) |  | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 6.6 | 151.8 | (72.7-279.1) |  | Male | 3 | 4.5 | nc | (nc-nc) |
| Female | 7 | 4.7 | 149.7 | (60.0-308.5) |  | Female | 8 | 12.2 | 65.8 | (28.3-129.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 5.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 15 | 14.9 | 100.7 | (56.3-166.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 13 | 28.6 | 45.4 | (24.1-77.6) |  | Male | 196 | 212.6 | 92.2 | (79.7-106.1) |
| Female | 30 | 30.3 | 98.9 | (66.7-141.2) |  | Female | 209 | 219.2 | 95.3 | (82.8-109.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

224

# Northbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 18 | 15.9 | 113.5 | (67.2-179.4) |  | Male | 9 | 10.7 | 84.1 | (38.4-159.7) |
| Female | 5 | 6.3 | 79.7 | (25.7-186.1) |  | Female | 8 | 8.9 | 89.7 | (38.6-176.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 3.2 | nc | (nc-nc) |  | Male | 8 | 3.4 | 232.6 | (100.2-458.4) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 9 | 9.4 | 95.6 | (43.6-181.5) |
| Female | 58 | 70.6 | 82.1 | (62.4-106.2) |  | Female | 12 | 8.7 | 137.9 | (71.2-240.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 8.4 | 94.9 | (40.9-187.1) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 2 | 3.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 17.6 | 51.1 | (23.3-97.0) |  |  |  |  |  |  |
| Female | 26 | 18.3 | 142.1 | (92.8-208.3) |  | Female | 4 | 6.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 4.3 | nc | (nc-nc) |  | Male | 5 | 6.1 | 81.9 | (26.4-191.2) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 7 | 6.5 | 106.9 | (42.8-220.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.2 | nc | (nc-nc) |  | Male | 50 | 51.9 | 96.4 | (71.5-127.1) |
| Female | 2 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 10.1 | 138.9 | (75.9-233.0) |  | Male | 5 | 3.9 | 129.1 | (41.6-301.2) |
| Female | 6 | 5.6 | 107.1 | (39.1-233.1) |  | Female | 3 | 2.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.5 | nc | (nc-nc) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 6.6 | nc | (nc-nc) |  | Male | 4 | 4.6 | nc | (nc-nc) |
| Female | 5 | 5.2 | 95.6 | (30.8-223.1) |  | Female | 12 | 13.6 | 88.2 | (45.5-154.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 6.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 18 | 15.4 | 116.7 | (69.1-184.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 27 | 28.6 | 94.5 | (62.3-137.6) |  | Male | 194 | 213.6 | 90.8 | (78.5-104.5) |
| Female | 30 | 32.3 | 93.0 | (62.7-132.7) |  | Female | 224 | 236.5 | 94.7 | (82.7-108.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

225

# Northfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 3.9 | nc | (nc-nc) |  | Male | 4 | 2.5 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 4 | 1.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 2.2 | nc | (nc-nc) |
| Female | 12 | 13.9 | 86.6 | (44.7-151.3) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 4.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 3.4 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 5 | 12.6 | 39.8 | (12.8-92.8) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 3 | 1.1 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 0 | 2.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 4 | 3.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 6.8 | nc | (nc-nc) |  | Male | 35 | 50.7 | 69.1 | (48.1-96.1) |
| Female | 4 | 6.1 | nc | (nc-nc) |  | Female | 41 | 45.5 | 90.1 | (64.7-122.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

226

# Norton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 18.7 | 69.6 | (37.0-119.0) |  | Male | 14 | 12.6 | 111.3 | (60.8-186.7) |
| Female | 9 | 6.0 | 149.6 | (68.3-284.0) |  | Female | 16 | 9.0 | 176.8 | (101.0-287.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 3.9 | 128.6 | (41.5-300.2) |  | Male | 4 | 4.0 | nc | (nc-nc) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 7 | 11.1 | 62.9 | (25.2-129.5) |
| Female | 77 | 74.2 | 103.7 | (81.8-129.6) |  | Female | 12 | 8.6 | 138.8 | (71.6-242.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 10.0 | 80.2 | (34.5-158.1) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 2 | 3.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 24 | 20.6 | 116.6 | (74.7-173.4) |  |  |  |  |  |  |
| Female | 22 | 17.7 | 124.6 | (78.1-188.7) |  | Female | 8 | 6.4 | 126.0 | (54.2-248.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 5.0 | 99.4 | (32.0-231.9) |  | Male | 9 | 7.2 | 125.6 | (57.3-238.5) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 10 | 6.2 | 161.2 | (77.2-296.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 54 | 62.3 | 86.7 | (65.1-113.1) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 15 | 11.9 | 126.0 | (70.5-207.8) |  | Male | 5 | 4.6 | 109.9 | (35.4-256.4) |
| Female | 7 | 5.8 | 121.3 | (48.6-249.9) |  | Female | 4 | 2.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 7.9 | 139.4 | (69.5-249.5) |  | Male | 6 | 5.5 | 109.1 | (39.8-237.4) |
| Female | 6 | 5.1 | 118.2 | (43.1-257.2) |  | Female | 15 | 14.3 | 104.6 | (58.5-172.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 7.2 | 83.3 | (30.4-181.3) |  |  |  |  |  |  |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 24 | 16.9 | 141.9 | (90.9-211.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 34 | 33.6 | 101.1 | (70.0-141.3) |  | Male | 248 | 253.3 | 97.9 | (86.1-110.9) |
| Female | 30 | 32.1 | 93.4 | (63.0-133.4) |  | Female | 272 | 241.1 | 112.8 | (99.8-127.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

227

# Norwell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 13.4 | 104.7 | (57.2-175.6) |  | Male | 9 | 8.5 | 105.8 | (48.3-200.9) |
| Female | 4 | 4.5 | nc | (nc-nc) |  | Female | 16 | 6.2 | 258.2 | (147.5-419.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 2.4 | 287.0 | (115.0-591.3) |  | Male | 1 | 2.7 | nc | (nc-nc) |
| Female | 4 | 2.0 | nc | (nc-nc) |  | Female | 6 | 2.1 | 289.9 | (105.9-631.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 5 | 7.5 | 66.7 | (21.5-155.7) |
| Female | 54 | 51.8 | 104.2 | (78.3-136.0) |  | Female | 9 | 6.1 | 146.9 | (67.0-278.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 6.3 | 80.0 | (25.8-186.7) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 5 | 2.7 | 182.7 | (58.9-426.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 14.1 | 78.0 | (38.9-139.7) |  |  |  |  |  |  |
| Female | 11 | 13.0 | 84.5 | (42.1-151.2) |  | Female | 6 | 4.4 | 137.9 | (50.4-300.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 3.3 | nc | (nc-nc) |  | Male | 7 | 4.9 | 142.2 | (57.0-292.9) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 4 | 4.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.8 | nc | (nc-nc) |  | Male | 37 | 38.4 | 96.3 | (67.8-132.7) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 7.6 | nc | (nc-nc) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 4 | 4.1 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 5.3 | 94.1 | (30.3-219.7) |  | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 4 | 3.6 | nc | (nc-nc) |  | Female | 4 | 9.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 4.6 | 152.0 | (60.9-313.1) |  |  |  |  |  |  |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 16 | 11.4 | 139.8 | (79.8-227.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 13 | 23.2 | 56.1 | (29.8-95.9) |  | Male | 153 | 166.9 | 91.7 | (77.7-107.4) |
| Female | 14 | 23.8 | 58.9 | (32.1-98.8) |  | Female | 182 | 169.8 | 107.2 | (92.2-123.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

228

# Norwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 32.4 | 34.0 | (16.9-60.8) |  | Male | 36 | 20.4 | 176.8 | (123.8-244.7) |
| Female | 7 | 13.2 | 53.0 | (21.3-109.3) |  | Female | 20 | 17.3 | 115.8 | (70.7-178.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 6.0 | 99.9 | (36.5-217.5) |  | Male | 8 | 6.5 | 123.6 | (53.2-243.5) |
| Female | 8 | 5.5 | 144.4 | (62.2-284.5) |  | Female | 7 | 6.0 | 116.7 | (46.8-240.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 18 | 18.0 | 100.2 | (59.3-158.3) |
| Female | 143 | 136.3 | 104.9 | (88.4-123.6) |  | Female | 19 | 17.6 | 108.2 | (65.1-169.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 16 | 14.3 | 112.2 | (64.1-182.3) |
| Female | 5 | 4.4 | 114.9 | (37.0-268.0) |  | Female | 7 | 7.6 | 92.5 | (37.1-190.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 49 | 33.3 | 147.2 | (108.9-194.6) |  |  |  |  |  |  |
| Female | 51 | 37.4 | 136.4 | (101.6-179.4) |  | Female | 11 | 11.9 | 92.4 | (46.1-165.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 7.8 | 102.6 | (44.2-202.1) |  | Male | 20 | 11.6 | 172.3 | (105.2-266.1) |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 20 | 13.8 | 145.1 | (88.6-224.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 78 | 87.7 | 88.9 | (70.3-110.9) |
| Female | 3 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 17.7 | 68.0 | (35.1-118.7) |  | Male | 9 | 7.5 | 120.8 | (55.1-229.3) |
| Female | 15 | 11.2 | 134.2 | (75.1-221.4) |  | Female | 4 | 5.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 4.5 | 134.1 | (49.0-292.0) |  | Male | 9 | 4.7 | 191.1 | (87.2-362.7) |
| Female | 3 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 14 | 12.9 | 108.5 | (59.2-182.0) |  | Male | 13 | 8.0 | 162.6 | (86.5-278.1) |
| Female | 11 | 10.4 | 105.7 | (52.7-189.2) |  | Female | 25 | 24.3 | 103.0 | (66.6-152.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 12 | 10.5 | 114.1 | (58.9-199.4) |  |  |  |  |  |  |
| Female | 3 | 4.2 | nc | (nc-nc) |  | Female | 32 | 30.2 | 106.0 | (72.5-149.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 58 | 55.7 | 104.0 | (79.0-134.5) |  | Male | 430 | 395.7 | 108.7 | (98.6-119.5) |
| Female | 93 | 68.1 | 136.5 | (110.2-167.3) |  | Female | 522 | 469.5 | 111.2 | (101.8-121.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

229

# Oak Bluffs

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 8.0 | 124.5 | (59.6-229.0) |  | Male | 8 | 4.9 | 162.6 | (70.0-320.4) |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 7 | 3.0 | 236.6 | (94.8-487.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 4 | 4.3 | nc | (nc-nc) |
| Female | 24 | 24.2 | 99.3 | (63.6-147.7) |  | Female | 1 | 3.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 3.4 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 3 | 1.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 7.7 | 104.0 | (44.8-204.9) |  |  |  |  |  |  |
| Female | 5 | 6.6 | 76.1 | (24.5-177.5) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  | Male | 4 | 2.9 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 16 | 23.0 | 69.5 | (39.7-112.8) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 4.3 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 3.0 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 4 | 4.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 5 | 5.5 | 91.5 | (29.5-213.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 12 | 14.6 | 82.1 | (42.3-143.3) |  | Male | 84 | 97.3 | 86.3 | (68.9-106.9) |
| Female | 13 | 12.0 | 108.6 | (57.8-185.7) |  | Female | 79 | 82.6 | 95.6 | (75.7-119.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

230

# Oakham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 2 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 2 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 8 | 8.0 | 100.0 | (43.1-197.1) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 2 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  | Male | 8 | 7.3 | 109.6 | (47.2-215.9) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 4 | 1.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 3.8 | 185.5 | (74.3-382.1) |  | Male | 26 | 28.6 | 90.9 | (59.4-133.2) |
| Female | 1 | 3.3 | nc | (nc-nc) |  | Female | 27 | 25.3 | 106.7 | (70.3-155.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

231

# Orange

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 9.1 | 88.1 | (37.9-173.6) |  | Male | 1 | 5.9 | nc | (nc-nc) |
| Female | 3 | 3.0 | nc | (nc-nc) |  | Female | 3 | 4.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 0 | 1.9 | nc | (nc-nc) |
| Female | 5 | 1.4 | 348.9 | (112.4-814.3) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 5 | 5.3 | 95.1 | (30.6-221.9) |
| Female | 32 | 37.9 | 84.4 | (57.7-119.1) |  | Female | 6 | 4.3 | 141.0 | (51.5-307.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 4.5 | 155.0 | (62.1-319.3) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 9.6 | 52.1 | (16.8-121.6) |  |  |  |  |  |  |
| Female | 8 | 8.7 | 92.5 | (39.8-182.2) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 2.4 | nc | (nc-nc) |  | Male | 4 | 3.4 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 3 | 3.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 25 | 28.8 | 86.7 | (56.1-127.9) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 5.4 | 110.1 | (40.2-239.7) |  | Male | 0 | 2.2 | nc | (nc-nc) |
| Female | 1 | 2.9 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 2 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.6 | nc | (nc-nc) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 5 | 6.9 | 72.3 | (23.3-168.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 3.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 10 | 8.8 | 113.7 | (54.4-209.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 21 | 16.4 | 128.0 | (79.2-195.7) |  | Male | 110 | 118.7 | 92.7 | (76.2-111.7) |
| Female | 17 | 16.2 | 105.1 | (61.2-168.3) |  | Female | 117 | 120.5 | 97.1 | (80.3-116.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

232

# Orleans

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 15.5 | 77.2 | (39.8-134.9) |  | Male | 21 | 8.6 | 242.8 | (150.3-371.2) |
| Female | 6 | 5.0 | 118.9 | (43.4-258.9) |  | Female | 9 | 5.5 | 163.8 | (74.7-310.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 3 | 2.9 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 13 | 7.5 | 172.5 | (91.8-295.1) |
| Female | 66 | 46.5 | 142.1 | (109.9-180.7) |  | Female | 7 | 6.3 | 111.3 | (44.6-229.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 5.5 | 90.8 | (29.3-212.0) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 5 | 2.7 | 184.6 | (59.5-430.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 13.7 | 102.1 | (55.7-171.2) |  |  |  |  |  |  |
| Female | 12 | 13.1 | 91.3 | (47.1-159.5) |  | Female | 6 | 4.1 | 146.9 | (53.7-319.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 3.6 | nc | (nc-nc) |  | Male | 5 | 5.3 | 94.2 | (30.4-219.8) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 8 | 5.3 | 151.9 | (65.4-299.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 36 | 40.8 | 88.3 | (61.9-122.3) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 7.1 | nc | (nc-nc) |  | Male | 1 | 3.4 | nc | (nc-nc) |
| Female | 1 | 4.0 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 5.2 | 133.4 | (53.4-274.9) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 2 | 3.5 | nc | (nc-nc) |  | Female | 3 | 5.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 4.4 | 113.7 | (36.7-265.4) |  |  |  |  |  |  |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 7 | 11.2 | 62.7 | (25.1-129.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 27.3 | 36.6 | (17.5-67.3) |  | Male | 160 | 172.9 | 92.5 | (78.7-108.0) |
| Female | 18 | 26.6 | 67.7 | (40.1-107.0) |  | Female | 180 | 164.0 | 109.7 | (94.3-127.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

233

# Otis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 2.8 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 13 | 8.5 | 153.2 | (81.5-262.1) |  | Female | 3 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 5 | 8.8 | 56.8 | (18.3-132.6) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 5.2 | 96.1 | (31.0-224.3) |  | Male | 18 | 35.6 | 50.5 | (29.9-79.8) |
| Female | 5 | 4.3 | 117.0 | (37.7-273.1) |  | Female | 29 | 28.3 | 102.4 | (68.5-147.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

234

# Oxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 11.1 | 171.4 | (103.1-267.7) |  | Male | 11 | 7.9 | 139.8 | (69.7-250.2) |
| Female | 6 | 4.8 | 124.6 | (45.5-271.2) |  | Female | 10 | 7.4 | 136.0 | (65.1-250.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 8 | 2.5 | 314.9 | (135.6-620.6) |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 5 | 2.3 | 217.5 | (70.1-507.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 11 | 7.0 | 157.3 | (78.4-281.5) |
| Female | 57 | 58.5 | 97.4 | (73.7-126.1) |  | Female | 9 | 6.9 | 130.2 | (59.4-247.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 6.5 | 153.1 | (73.3-281.6) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 4 | 3.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 12.8 | 78.4 | (37.5-144.2) |  |  |  |  |  |  |
| Female | 18 | 14.2 | 126.7 | (75.1-200.3) |  | Female | 9 | 5.0 | 179.8 | (82.0-341.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 3.2 | nc | (nc-nc) |  | Male | 5 | 4.4 | 112.9 | (36.4-263.5) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 6 | 5.0 | 120.1 | (43.9-261.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 43 | 41.3 | 104.1 | (75.3-140.2) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 7.9 | 76.4 | (27.9-166.2) |  | Male | 1 | 2.8 | nc | (nc-nc) |
| Female | 9 | 4.6 | 196.9 | (89.8-373.7) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 1.9 | 262.1 | (84.5-611.7) |  | Male | 4 | 2.1 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 4.9 | 202.9 | (97.1-373.1) |  | Male | 8 | 3.8 | 212.3 | (91.4-418.3) |
| Female | 6 | 4.1 | 145.0 | (53.0-315.6) |  | Female | 14 | 11.7 | 119.6 | (65.3-200.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 4.7 | 148.8 | (59.6-306.7) |  |  |  |  |  |  |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 22 | 13.2 | 166.5 | (104.3-252.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 29 | 20.7 | 140.4 | (94.0-201.6) |  | Male | 203 | 161.0 | 126.1 | (109.3-144.7) |
| Female | 25 | 25.3 | 98.7 | (63.9-145.8) |  | Female | 230 | 191.7 | 120.0 | (105.0-136.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

235

# Palmer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 13.3 | 128.0 | (74.5-205.0) |  | Male | 13 | 8.8 | 148.5 | (79.0-254.0) |
| Female | 8 | 5.4 | 149.1 | (64.2-293.9) |  | Female | 7 | 7.2 | 96.8 | (38.8-199.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 2.6 | 269.5 | (108.0-555.3) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 6 | 7.7 | 77.9 | (28.4-169.6) |
| Female | 63 | 59.5 | 105.8 | (81.3-135.4) |  | Female | 8 | 7.3 | 110.0 | (47.4-216.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 6.7 | 89.0 | (32.5-193.7) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 2 | 3.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 14.3 | 83.9 | (43.3-146.5) |  |  |  |  |  |  |
| Female | 13 | 14.9 | 87.0 | (46.3-148.8) |  | Female | 8 | 5.1 | 157.4 | (67.8-310.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 4 | 5.0 | nc | (nc-nc) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 7 | 5.7 | 123.8 | (49.6-255.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 32 | 42.1 | 76.1 | (52.0-107.4) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 8.1 | 173.3 | (94.7-290.8) |  | Male | 6 | 3.2 | 188.7 | (68.9-410.7) |
| Female | 6 | 4.8 | 125.9 | (46.0-274.0) |  | Female | 3 | 2.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 2.0 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 5.4 | 92.7 | (29.9-216.4) |  | Male | 1 | 3.6 | nc | (nc-nc) |
| Female | 4 | 4.2 | nc | (nc-nc) |  | Female | 7 | 10.3 | 67.7 | (27.1-139.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 4.9 | 101.2 | (32.6-236.1) |  |  |  |  |  |  |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 8 | 14.0 | 57.3 | (24.7-113.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 29 | 23.8 | 121.7 | (81.5-174.8) |  | Male | 183 | 174.6 | 104.8 | (90.2-121.1) |
| Female | 20 | 28.5 | 70.1 | (42.8-108.3) |  | Female | 186 | 199.4 | 93.3 | (80.4-107.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

236

# Paxton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 5.8 | 137.2 | (59.1-270.4) |  | Male | 5 | 3.7 | 135.3 | (43.6-315.6) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 3 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.2 | nc | (nc-nc) |  | Male | 1 | 3.3 | nc | (nc-nc) |
| Female | 19 | 21.0 | 90.5 | (54.5-141.4) |  | Female | 2 | 2.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 2.9 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 6.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 4.9 | nc | (nc-nc) |  | Female | 0 | 1.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 1.5 | nc | (nc-nc) |  | Male | 4 | 2.2 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 22 | 18.4 | 119.3 | (74.8-180.7) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 3.4 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 2.3 | 213.7 | (68.9-498.6) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 1 | 3.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 7 | 5.0 | 141.2 | (56.6-290.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 10.3 | 48.8 | (15.7-113.8) |  | Male | 79 | 75.0 | 105.3 | (83.4-131.2) |
| Female | 4 | 9.4 | nc | (nc-nc) |  | Female | 52 | 68.1 | 76.4 | (57.0-100.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

237

# Peabody

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 100 | 73.3 | 136.4 | (110.9-165.8) |  | Male | 41 | 43.9 | 93.3 | (66.9-126.6) |
| Female | 38 | 28.0 | 135.6 | (96.0-186.2) |  | Female | 33 | 34.3 | 96.1 | (66.1-134.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 12.0 | 58.1 | (23.3-119.8) |  | Male | 21 | 14.3 | 147.4 | (91.2-225.3) |
| Female | 15 | 10.9 | 137.1 | (76.7-226.1) |  | Female | 14 | 12.5 | 111.7 | (61.0-187.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 41 | 38.9 | 105.5 | (75.7-143.1) |
| Female | 294 | 269.0 | 109.3 | (97.2-122.5) |  | Female | 60 | 36.2 | 165.8 | (126.5-213.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 28 | 30.0 | 93.2 | (61.9-134.7) |
| Female | 11 | 8.2 | 134.3 | (67.0-240.4) |  | Female | 17 | 15.5 | 109.5 | (63.8-175.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 63 | 72.0 | 87.5 | (67.2-112.0) |  |  |  |  |  |  |
| Female | 79 | 78.9 | 100.2 | (79.3-124.8) |  | Female | 20 | 23.9 | 83.8 | (51.2-129.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 14 | 17.2 | 81.3 | (44.4-136.4) |  | Male | 26 | 25.9 | 100.4 | (65.6-147.1) |
| Female | 3 | 5.3 | nc | (nc-nc) |  | Female | 27 | 29.7 | 91.0 | (60.0-132.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 4.2 | nc | (nc-nc) |  | Male | 200 | 194.0 | 103.1 | (89.3-118.4) |
| Female | 4 | 3.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 36 | 37.1 | 97.0 | (68.0-134.4) |  | Male | 17 | 16.4 | 103.5 | (60.2-165.7) |
| Female | 14 | 22.4 | 62.5 | (34.1-104.9) |  | Female | 8 | 11.1 | 71.8 | (30.9-141.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 18 | 9.8 | 183.3 | (108.5-289.6) |  | Male | 7 | 7.3 | 95.9 | (38.4-197.6) |
| Female | 1 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 30 | 27.7 | 108.4 | (73.1-154.7) |  | Male | 12 | 15.2 | 79.2 | (40.9-138.3) |
| Female | 29 | 21.5 | 134.9 | (90.3-193.7) |  | Female | 50 | 44.4 | 112.6 | (83.6-148.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 16 | 23.2 | 69.1 | (39.5-112.2) |  |  |  |  |  |  |
| Female | 12 | 8.8 | 135.9 | (70.1-237.3) |  | Female | 45 | 60.3 | 74.6 | (54.4-99.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 124 | 124.1 | 99.9 | (83.1-119.1) |  | Male | 898 | 861.4 | 104.3 | (97.5-111.3) |
| Female | 153 | 139.7 | 109.5 | (92.8-128.3) |  | Female | 1022 | 950.2 | 107.6 | (101.1-114.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

238

# Pelham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 3 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 4 | 7.8 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 6.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 3.5 | nc | (nc-nc) |  | Male | 18 | 25.1 | 71.7 | (42.5-113.3) |
| Female | 3 | 3.8 | nc | (nc-nc) |  | Female | 16 | 26.1 | 61.3 | (35.0-99.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

239

# Pembroke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 17.8 | 107.0 | (64.4-167.1) |  | Male | 11 | 12.1 | 90.7 | (45.2-162.2) |
| Female | 6 | 6.1 | 98.1 | (35.8-213.5) |  | Female | 15 | 9.6 | 156.3 | (87.4-257.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 3.7 | 134.1 | (43.2-312.9) |  | Male | 2 | 3.9 | nc | (nc-nc) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 2 | 3.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 13 | 10.7 | 121.6 | (64.7-207.9) |
| Female | 76 | 79.4 | 95.8 | (75.4-119.9) |  | Female | 7 | 9.1 | 77.2 | (30.9-159.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 9.8 | 111.8 | (55.7-200.1) |
| Female | 2 | 2.7 | nc | (nc-nc) |  | Female | 3 | 4.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 28 | 19.7 | 141.9 | (94.3-205.1) |  |  |  |  |  |  |
| Female | 18 | 18.2 | 99.1 | (58.7-156.7) |  | Female | 5 | 6.7 | 74.9 | (24.1-174.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 4.9 | 141.6 | (56.7-291.8) |  | Male | 7 | 6.9 | 101.2 | (40.6-208.6) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 4 | 6.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 59 | 61.5 | 95.9 | (73.0-123.7) |
| Female | 2 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 11.6 | 146.1 | (85.0-233.9) |  | Male | 7 | 4.4 | 160.0 | (64.1-329.6) |
| Female | 7 | 6.1 | 115.6 | (46.3-238.2) |  | Female | 1 | 2.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 5 | 2.8 | 178.3 | (57.5-416.2) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 7.5 | 93.9 | (37.6-193.5) |  | Male | 7 | 5.4 | 129.1 | (51.7-266.0) |
| Female | 6 | 5.1 | 116.8 | (42.6-254.2) |  | Female | 26 | 15.4 | 168.4 | (110.0-246.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 7.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 19 | 18.3 | 103.6 | (62.3-161.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 39 | 32.2 | 121.3 | (86.2-165.8) |  | Male | 273 | 245.3 | 111.3 | (98.5-125.3) |
| Female | 42 | 32.9 | 127.8 | (92.1-172.7) |  | Female | 261 | 252.9 | 103.2 | (91.1-116.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

240

# Pepperell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 12.0 | 91.7 | (45.7-164.1) |  | Male | 4 | 8.1 | nc | (nc-nc) |
| Female | 3 | 4.0 | nc | (nc-nc) |  | Female | 5 | 6.3 | 78.9 | (25.4-184.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.5 | nc | (nc-nc) |  | Male | 1 | 2.7 | nc | (nc-nc) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 5 | 7.2 | 69.6 | (22.4-162.3) |
| Female | 49 | 53.1 | 92.2 | (68.2-121.9) |  | Female | 3 | 5.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 6.6 | 91.2 | (33.3-198.4) |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 1 | 2.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 15 | 13.4 | 111.7 | (62.5-184.2) |  |  |  |  |  |  |
| Female | 16 | 11.9 | 134.4 | (76.8-218.3) |  | Female | 5 | 4.4 | 113.0 | (36.4-263.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 3.3 | 151.5 | (48.8-353.5) |  | Male | 6 | 4.7 | 128.9 | (47.1-280.7) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 2 | 4.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 23 | 40.6 | 56.6 | (35.9-84.9) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 7.8 | 89.6 | (35.9-184.7) |  | Male | 3 | 2.9 | nc | (nc-nc) |
| Female | 6 | 4.0 | 148.5 | (54.2-323.1) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 1.9 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 5.0 | nc | (nc-nc) |  | Male | 6 | 3.5 | 169.6 | (61.9-369.3) |
| Female | 4 | 3.4 | nc | (nc-nc) |  | Female | 9 | 10.5 | 86.1 | (39.3-163.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 4.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 16 | 12.0 | 133.5 | (76.3-216.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 24 | 21.7 | 110.6 | (70.8-164.6) |  | Male | 142 | 164.0 | 86.6 | (72.9-102.0) |
| Female | 16 | 21.9 | 73.1 | (41.8-118.8) |  | Female | 151 | 167.7 | 90.1 | (76.3-105.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

241

# Peru

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 3.8 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 10 | 13.4 | 74.8 | (35.8-137.6) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 2 | 11.8 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

242

# Petersham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 1.8 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 0.9 | nc | (nc-nc) |
| Female | 5 | 6.6 | 76.0 | (24.5-177.3) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 5 | 5.1 | 98.8 | (31.8-230.6) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  | Male | 21 | 21.2 | 99.0 | (61.2-151.3) |
| Female | 1 | 3.1 | nc | (nc-nc) |  | Female | 13 | 21.9 | 59.4 | (31.6-101.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

243

# Phillipston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 3 | 8.2 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 2 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 9 | 5.9 | 153.0 | (69.8-290.4) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 2.8 | nc | (nc-nc) |  | Male | 26 | 22.5 | 115.7 | (75.5-169.5) |
| Female | 3 | 3.1 | nc | (nc-nc) |  | Female | 15 | 25.3 | 59.3 | (33.1-97.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

244

# Pittsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 72 | 55.8 | 129.1 | (101.0-162.5) |  | Male | 29 | 34.4 | 84.3 | (56.4-121.1) |
| Female | 24 | 20.4 | 117.5 | (75.2-174.8) |  | Female | 21 | 26.7 | 78.6 | (48.6-120.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 13 | 9.8 | 132.5 | (70.5-226.6) |  | Male | 8 | 11.1 | 72.1 | (31.0-142.0) |
| Female | 6 | 8.6 | 69.5 | (25.4-151.4) |  | Female | 2 | 9.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  | Male | 30 | 30.4 | 98.7 | (66.6-140.9) |
| Female | 206 | 214.1 | 96.2 | (83.5-110.3) |  | Female | 27 | 27.2 | 99.2 | (65.3-144.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 33 | 24.9 | 132.8 | (91.4-186.5) |
| Female | 5 | 6.6 | 75.9 | (24.5-177.2) |  | Female | 12 | 11.9 | 100.5 | (51.8-175.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 61 | 56.5 | 108.0 | (82.6-138.8) |  |  |  |  |  |  |
| Female | 85 | 57.2 | 148.7 | (118.8-183.8) |  | Female | 16 | 18.7 | 85.5 | (48.8-138.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 24 | 13.7 | 175.6 | (112.5-261.3) |  | Male | 20 | 20.2 | 99.0 | (60.4-152.9) |
| Female | 5 | 3.9 | 126.6 | (40.8-295.5) |  | Female | 25 | 21.3 | 117.3 | (75.9-173.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 3.6 | 139.5 | (45.0-325.6) |  | Male | 157 | 162.5 | 96.6 | (82.1-113.0) |
| Female | 1 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 33 | 30.4 | 108.7 | (74.8-152.7) |  | Male | 14 | 12.8 | 109.4 | (59.8-183.6) |
| Female | 25 | 17.5 | 142.9 | (92.4-210.9) |  | Female | 8 | 8.1 | 99.1 | (42.7-195.2) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 9 | 7.9 | 114.4 | (52.2-217.3) |  | Male | 8 | 6.4 | 124.5 | (53.6-245.3) |
| Female | 1 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 23 | 21.7 | 106.1 | (67.3-159.3) |  | Male | 10 | 12.7 | 78.5 | (37.6-144.3) |
| Female | 10 | 16.1 | 62.3 | (29.8-114.6) |  | Female | 33 | 37.1 | 89.0 | (61.3-125.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 20 | 18.7 | 107.0 | (65.3-165.3) |  |  |  |  |  |  |
| Female | 6 | 6.7 | 90.0 | (32.9-195.9) |  | Female | 67 | 49.1 | 136.4 | (105.7-173.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 117 | 96.3 | 121.5 | (100.4-145.6) |  | Male | 746 | 686.6 | 108.7 | (101.0-116.7) |
| Female | 131 | 106.3 | 123.3 | (103.1-146.3) |  | Female | 771 | 732.7 | 105.2 | (97.9-112.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

245

# Plainfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 4 | 3.4 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 3.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 7 | 12.8 | 54.7 | (21.9-112.7) |
| Female | 5 | 1.6 | 320.4 | (103.3-747.8) |  | Female | 13 | 11.0 | 118.2 | (62.9-202.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

246

# Plainville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 7.7 | 116.3 | (53.1-220.7) |  | Male | 7 | 5.5 | 127.1 | (50.9-262.0) |
| Female | 2 | 3.2 | nc | (nc-nc) |  | Female | 3 | 4.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 4 | 1.8 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.3 | nc | (nc-nc) |  | Male | 7 | 4.9 | 143.3 | (57.4-295.3) |
| Female | 39 | 37.3 | 104.5 | (74.3-142.8) |  | Female | 1 | 4.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 4.5 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 9.2 | 108.9 | (52.1-200.3) |  |  |  |  |  |  |
| Female | 8 | 9.3 | 86.2 | (37.1-169.9) |  | Female | 4 | 3.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 6 | 3.1 | 195.0 | (71.2-424.4) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 32 | 27.3 | 117.3 | (80.2-165.6) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 5.4 | 222.8 | (115.0-389.2) |  | Male | 0 | 2.0 | nc | (nc-nc) |
| Female | 3 | 3.0 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 3.4 | 148.8 | (47.9-347.2) |  | Male | 1 | 2.7 | nc | (nc-nc) |
| Female | 6 | 2.6 | 226.9 | (82.8-493.9) |  | Female | 7 | 7.4 | 94.9 | (38.0-195.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 9 | 8.3 | 107.9 | (49.2-204.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 23 | 14.0 | 164.7 | (104.4-247.2) |  | Male | 139 | 110.4 | 125.9 | (105.9-148.7) |
| Female | 17 | 16.5 | 102.7 | (59.8-164.5) |  | Female | 119 | 123.1 | 96.7 | (80.1-115.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

247

# Plymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 67 | 68.6 | 97.6 | (75.6-124.0) |  | Male | 76 | 44.6 | 170.2 | (134.1-213.1) |
| Female | 27 | 24.9 | 108.3 | (71.4-157.6) |  | Female | 50 | 34.4 | 145.3 | (107.9-191.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 12 | 13.1 | 91.6 | (47.3-160.0) |  | Male | 10 | 14.5 | 68.9 | (33.0-126.8) |
| Female | 11 | 11.1 | 99.3 | (49.5-177.7) |  | Female | 11 | 11.8 | 93.4 | (46.5-167.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 50 | 39.4 | 126.8 | (94.1-167.2) |
| Female | 305 | 288.0 | 105.9 | (94.4-118.5) |  | Female | 27 | 34.3 | 78.7 | (51.8-114.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 34 | 34.2 | 99.3 | (68.8-138.8) |
| Female | 6 | 9.0 | 66.7 | (24.4-145.2) |  | Female | 20 | 15.5 | 129.0 | (78.7-199.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 60 | 71.8 | 83.6 | (63.8-107.6) |  |  |  |  |  |  |
| Female | 56 | 70.0 | 80.0 | (60.4-103.9) |  | Female | 33 | 24.4 | 135.0 | (92.9-189.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 18 | 18.1 | 99.5 | (58.9-157.3) |  | Male | 27 | 26.0 | 104.0 | (68.5-151.3) |
| Female | 1 | 5.0 | nc | (nc-nc) |  | Female | 21 | 26.0 | 80.8 | (50.0-123.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 4.9 | nc | (nc-nc) |  | Male | 229 | 225.1 | 101.8 | (89.0-115.8) |
| Female | 2 | 3.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 43 | 41.6 | 103.4 | (74.8-139.3) |  | Male | 14 | 16.3 | 85.7 | (46.8-143.8) |
| Female | 22 | 22.8 | 96.4 | (60.4-145.9) |  | Female | 12 | 9.8 | 122.2 | (63.1-213.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 9 | 10.6 | 84.6 | (38.6-160.5) |  | Male | 9 | 8.8 | 102.3 | (46.7-194.1) |
| Female | 1 | 3.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 28 | 27.5 | 101.7 | (67.6-147.0) |  | Male | 22 | 18.1 | 121.7 | (76.2-184.2) |
| Female | 16 | 19.6 | 81.6 | (46.6-132.5) |  | Female | 72 | 50.2 | 143.4 | (112.2-180.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 30 | 25.2 | 118.9 | (80.2-169.7) |  |  |  |  |  |  |
| Female | 7 | 8.4 | 83.6 | (33.5-172.3) |  | Female | 79 | 67.3 | 117.3 | (92.9-146.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 127 | 124.5 | 102.0 | (85.0-121.4) |  | Male | 961 | 903.4 | 106.4 | (99.8-113.3) |
| Female | 148 | 134.8 | 109.8 | (92.8-129.0) |  | Female | 1006 | 947.9 | 106.1 | (99.7-112.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

248

# Plympton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 3.8 | 132.4 | (42.7-308.9) |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 14 | 12.7 | 110.0 | (60.1-184.7) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 3 | 0.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 3.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 2.7 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 3 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 15 | 12.8 | 117.5 | (65.7-193.8) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 3 | 1.0 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 6.9 | nc | (nc-nc) |  | Male | 46 | 50.1 | 91.9 | (67.3-122.6) |
| Female | 7 | 5.4 | 129.6 | (51.9-267.0) |  | Female | 49 | 40.1 | 122.1 | (90.3-161.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

249

# Princeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 3.5 | 141.2 | (45.5-329.5) |  | Male | 6 | 2.5 | 240.4 | (87.8-523.2) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 3 | 1.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 21 | 17.0 | 123.5 | (76.4-188.7) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 2.2 | 508.0 | (253.2-908.9) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 4.1 | 122.8 | (39.6-286.5) |  |  |  |  |  |  |
| Female | 2 | 3.4 | nc | (nc-nc) |  | Female | 5 | 1.4 | 359.5 | (115.9-838.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 1.1 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 11 | 13.8 | 79.8 | (39.8-142.8) |
| Female | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 2.5 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 3 | 3.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 4 | 4.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 6.7 | nc | (nc-nc) |  | Male | 63 | 51.9 | 121.5 | (93.3-155.4) |
| Female | 3 | 7.0 | nc | (nc-nc) |  | Female | 50 | 52.3 | 95.6 | (70.9-126.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

250

# Provincetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 6.2 | nc | (nc-nc) |  | Male | 3 | 3.7 | nc | (nc-nc) |
| Female | 7 | 2.1 | 329.5 | (132.0-679.0) |  | Female | 5 | 2.4 | 205.2 | (66.1-478.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 3.3 | nc | (nc-nc) |
| Female | 23 | 21.0 | 109.8 | (69.6-164.7) |  | Female | 1 | 2.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 2.8 | 246.5 | (98.7-507.8) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 4 | 1.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 6.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 11 | 5.5 | 199.6 | (99.5-357.1) |  | Female | 4 | 1.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 4 | 2.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 10 | 19.4 | 51.6 | (24.7-94.9) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 3.4 | 146.0 | (47.1-340.8) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 4 | 5.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 10.9 | 101.3 | (50.5-181.2) |  | Male | 66 | 76.7 | 86.1 | (66.6-109.5) |
| Female | 11 | 11.4 | 96.3 | (48.0-172.2) |  | Female | 88 | 72.0 | 122.3 | (98.1-150.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

251

# Quincy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 100 | 95.9 | 104.3 | (84.9-126.9) |  | Male | 57 | 62.1 | 91.8 | (69.6-119.0) |
| Female | 35 | 36.0 | 97.2 | (67.7-135.2) |  | Female | 55 | 50.0 | 110.0 | (82.9-143.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 19 | 18.8 | 100.8 | (60.7-157.4) |  | Male | 14 | 19.7 | 71.1 | (38.9-119.4) |
| Female | 17 | 16.2 | 105.0 | (61.1-168.1) |  | Female | 14 | 16.6 | 84.5 | (46.1-141.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 5 | 3.4 | 149.1 | (48.1-348.0) |  | Male | 50 | 55.1 | 90.7 | (67.3-119.5) |
| Female | 400 | 389.7 | 102.6 | (92.8-113.2) |  | Female | 57 | 49.0 | 116.4 | (88.2-150.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 61 | 45.2 | 135.0 | (103.3-173.4) |
| Female | 21 | 12.8 | 164.7 | (101.9-251.8) |  | Female | 29 | 21.6 | 134.2 | (89.9-192.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 125 | 100.6 | 124.3 | (103.5-148.1) |  |  |  |  |  |  |
| Female | 103 | 102.4 | 100.6 | (82.1-122.0) |  | Female | 34 | 34.3 | 99.0 | (68.6-138.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 23 | 24.0 | 95.9 | (60.8-143.9) |  | Male | 30 | 35.4 | 84.9 | (57.2-121.1) |
| Female | 8 | 6.9 | 115.7 | (49.8-227.9) |  | Female | 29 | 37.4 | 77.5 | (51.9-111.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 10 | 8.2 | 122.5 | (58.7-225.4) |  | Male | 257 | 281.8 | 91.2 | (80.4-103.1) |
| Female | 10 | 7.1 | 140.5 | (67.3-258.4) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 53 | 55.1 | 96.2 | (72.1-125.9) |  | Male | 30 | 22.5 | 133.5 | (90.0-190.5) |
| Female | 34 | 31.7 | 107.1 | (74.2-149.7) |  | Female | 17 | 14.3 | 118.6 | (69.0-189.9) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 18 | 14.0 | 128.4 | (76.1-202.9) |  | Male | 17 | 16.2 | 105.2 | (61.3-168.5) |
| Female | 4 | 4.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 23 | 39.2 | 58.6 | (37.1-88.0) |  | Male | 36 | 25.7 | 140.2 | (98.2-194.2) |
| Female | 30 | 29.2 | 102.6 | (69.2-146.5) |  | Female | 65 | 74.2 | 87.5 | (67.6-111.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 57 | 33.6 | 169.6 | (128.4-219.7) |  |  |  |  |  |  |
| Female | 17 | 11.9 | 142.5 | (83.0-228.2) |  | Female | 87 | 89.0 | 97.8 | (78.3-120.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 237 | 167.4 | 141.6 | (124.1-160.8) |  | Male | 1316 | 1222.0 | 107.7 | (102.0-113.7) |
| Female | 241 | 188.2 | 128.0 | (112.4-145.3) |  | Female | 1406 | 1330.3 | 105.7 | (100.2-111.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

252

# Randolph

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 33 | 34.7 | 95.0 | (65.4-133.4) |  | Male | 12 | 22.4 | 53.5 | (27.6-93.5) |
| Female | 11 | 14.1 | 78.0 | (38.9-139.6) |  | Female | 13 | 19.6 | 66.4 | (35.3-113.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 6.7 | 119.3 | (51.4-235.0) |  | Male | 8 | 7.2 | 111.4 | (48.0-219.5) |
| Female | 5 | 6.3 | 79.0 | (25.4-184.3) |  | Female | 7 | 6.6 | 105.7 | (42.3-217.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 12 | 19.9 | 60.2 | (31.1-105.2) |
| Female | 145 | 157.0 | 92.4 | (78.0-108.7) |  | Female | 22 | 19.5 | 113.1 | (70.8-171.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 17.1 | 52.7 | (24.0-100.0) |
| Female | 3 | 5.1 | nc | (nc-nc) |  | Female | 6 | 8.6 | 69.7 | (25.4-151.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 35 | 37.1 | 94.2 | (65.6-131.1) |  |  |  |  |  |  |
| Female | 46 | 40.1 | 114.8 | (84.0-153.1) |  | Female | 11 | 13.6 | 81.0 | (40.4-145.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 8.9 | 90.2 | (38.8-177.7) |  | Male | 10 | 12.9 | 77.2 | (37.0-142.1) |
| Female | 2 | 2.8 | nc | (nc-nc) |  | Female | 10 | 14.7 | 67.9 | (32.5-124.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  | Male | 101 | 107.4 | 94.1 | (76.6-114.3) |
| Female | 2 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 29 | 20.5 | 141.6 | (94.8-203.3) |  | Male | 10 | 8.2 | 122.0 | (58.4-224.3) |
| Female | 8 | 12.6 | 63.7 | (27.4-125.5) |  | Female | 6 | 5.7 | 106.1 | (38.7-230.9) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 5.1 | 136.8 | (54.8-282.0) |  | Male | 0 | 5.0 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 14.1 | 77.9 | (38.8-139.3) |  | Male | 13 | 9.2 | 141.4 | (75.2-241.7) |
| Female | 2 | 11.3 | nc | (nc-nc) |  | Female | 35 | 28.9 | 121.1 | (84.3-168.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 15 | 12.5 | 119.9 | (67.1-197.8) |  |  |  |  |  |  |
| Female | 1 | 4.7 | nc | (nc-nc) |  | Female | 41 | 36.3 | 113.0 | (81.1-153.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 44 | 60.2 | 73.1 | (53.1-98.1) |  | Male | 391 | 448.5 | 87.2 | (78.8-96.3) |
| Female | 52 | 73.7 | 70.6 | (52.7-92.6) |  | Female | 461 | 527.4 | 87.4 | (79.6-95.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

253

# Raynham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 14.5 | 89.5 | (47.6-153.1) |  | Male | 11 | 9.6 | 114.6 | (57.2-205.1) |
| Female | 6 | 5.7 | 105.7 | (38.6-230.0) |  | Female | 11 | 7.8 | 141.1 | (70.4-252.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.9 | nc | (nc-nc) |  | Male | 4 | 3.1 | nc | (nc-nc) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 12 | 8.4 | 143.0 | (73.8-249.8) |
| Female | 69 | 63.2 | 109.3 | (85.0-138.3) |  | Female | 7 | 7.8 | 89.9 | (36.0-185.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 7.5 | 67.0 | (21.6-156.4) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 4 | 3.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 26 | 15.7 | 165.9 | (108.4-243.1) |  |  |  |  |  |  |
| Female | 17 | 15.9 | 107.1 | (62.3-171.5) |  | Female | 9 | 5.4 | 166.5 | (76.0-316.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 3.8 | 157.8 | (57.6-343.4) |  | Male | 5 | 5.5 | 90.8 | (29.3-211.8) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 5 | 5.8 | 85.6 | (27.6-199.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 48 | 46.6 | 102.9 | (75.9-136.5) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 8.9 | 135.5 | (69.9-236.7) |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 6 | 5.1 | 118.2 | (43.2-257.3) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 4 | 2.0 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 6.0 | nc | (nc-nc) |  | Male | 6 | 3.9 | 153.2 | (55.9-333.5) |
| Female | 4 | 4.5 | nc | (nc-nc) |  | Female | 24 | 11.5 | 208.2 | (133.4-309.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 5.5 | 108.4 | (39.6-236.0) |  |  |  |  |  |  |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 16 | 14.3 | 112.1 | (64.1-182.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 23 | 26.0 | 88.5 | (56.1-132.7) |  | Male | 213 | 191.8 | 111.1 | (96.6-127.0) |
| Female | 26 | 30.4 | 85.4 | (55.8-125.2) |  | Female | 238 | 211.5 | 112.5 | (98.7-127.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

254

# Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 26 | 25.7 | 101.2 | (66.1-148.2) |  | Male | 14 | 16.7 | 83.8 | (45.8-140.6) |
| Female | 11 | 10.3 | 106.8 | (53.2-191.1) |  | Female | 15 | 14.3 | 104.9 | (58.7-173.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 5.0 | nc | (nc-nc) |  | Male | 4 | 5.3 | nc | (nc-nc) |
| Female | 6 | 4.6 | 130.2 | (47.5-283.4) |  | Female | 2 | 4.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 17 | 14.8 | 114.6 | (66.7-183.5) |
| Female | 129 | 112.7 | 114.5 | (95.6-136.0) |  | Female | 8 | 14.0 | 57.0 | (24.6-112.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 14 | 12.7 | 110.1 | (60.2-184.8) |
| Female | 2 | 3.8 | nc | (nc-nc) |  | Female | 6 | 6.2 | 97.1 | (35.4-211.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 32 | 27.6 | 116.0 | (79.3-163.8) |  |  |  |  |  |  |
| Female | 27 | 29.9 | 90.4 | (59.6-131.5) |  | Female | 14 | 9.7 | 143.8 | (78.6-241.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 6.6 | 75.9 | (24.5-177.1) |  | Male | 9 | 9.6 | 94.0 | (42.9-178.5) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 9 | 10.8 | 83.0 | (37.9-157.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 66 | 79.4 | 83.2 | (64.3-105.8) |
| Female | 2 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 16 | 15.3 | 104.5 | (59.7-169.7) |  | Male | 2 | 6.1 | nc | (nc-nc) |
| Female | 8 | 9.0 | 88.7 | (38.2-174.7) |  | Female | 1 | 4.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.8 | nc | (nc-nc) |  | Male | 6 | 3.7 | 161.0 | (58.8-350.5) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 10.6 | 123.1 | (65.5-210.4) |  | Male | 8 | 7.0 | 114.0 | (49.1-224.6) |
| Female | 9 | 8.4 | 106.8 | (48.7-202.7) |  | Female | 25 | 21.0 | 119.2 | (77.1-175.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 11 | 9.3 | 117.9 | (58.8-211.0) |  |  |  |  |  |  |
| Female | 4 | 3.4 | nc | (nc-nc) |  | Female | 24 | 25.1 | 95.7 | (61.3-142.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 32 | 44.5 | 72.0 | (49.2-101.6) |  | Male | 307 | 332.9 | 92.2 | (82.2-103.1) |
| Female | 37 | 52.5 | 70.4 | (49.6-97.1) |  | Female | 378 | 381.0 | 99.2 | (89.5-109.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

255

# Rehoboth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 14.9 | nc | (nc-nc) |  | Male | 8 | 9.5 | 84.2 | (36.3-166.0) |
| Female | 5 | 3.7 | 134.3 | (43.3-313.4) |  | Female | 6 | 5.9 | 102.0 | (37.2-222.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 2.7 | nc | (nc-nc) |  | Male | 3 | 3.1 | nc | (nc-nc) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 9 | 8.4 | 107.0 | (48.8-203.2) |
| Female | 51 | 49.1 | 103.8 | (77.3-136.5) |  | Female | 7 | 5.5 | 127.8 | (51.2-263.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 7.2 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 3 | 2.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 15.7 | 57.2 | (26.1-108.7) |  |  |  |  |  |  |
| Female | 9 | 10.8 | 83.7 | (38.2-158.8) |  | Female | 4 | 4.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 3.8 | nc | (nc-nc) |  | Male | 1 | 5.5 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 2 | 3.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 35 | 45.9 | 76.2 | (53.1-106.0) |
| Female | 2 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 8.6 | 81.0 | (32.5-166.9) |  | Male | 1 | 3.5 | nc | (nc-nc) |
| Female | 5 | 3.8 | 132.9 | (42.8-310.2) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 2 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 5.9 | 84.8 | (27.3-197.9) |  | Male | 0 | 3.7 | nc | (nc-nc) |
| Female | 2 | 3.2 | nc | (nc-nc) |  | Female | 10 | 9.6 | 104.3 | (49.9-191.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 5.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 16 | 11.7 | 137.3 | (78.4-223.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 24 | 25.8 | 92.9 | (59.5-138.2) |  | Male | 124 | 190.2 | 65.2 | (54.2-77.7) |
| Female | 17 | 20.4 | 83.3 | (48.5-133.4) |  | Female | 154 | 156.0 | 98.7 | (83.8-115.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

256

# Revere

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 52 | 52.2 | 99.5 | (74.3-130.5) |  | Male | 18 | 34.9 | 51.6 | (30.5-81.5) |
| Female | 18 | 19.8 | 90.9 | (53.8-143.7) |  | Female | 20 | 27.4 | 73.1 | (44.6-112.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 10.9 | 64.2 | (25.7-132.4) |  | Male | 7 | 10.9 | 64.1 | (25.7-132.1) |
| Female | 12 | 8.9 | 135.2 | (69.8-236.1) |  | Female | 10 | 9.1 | 109.4 | (52.4-201.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 30 | 30.9 | 97.0 | (65.4-138.5) |
| Female | 190 | 216.0 | 87.9 | (75.9-101.4) |  | Female | 25 | 27.0 | 92.7 | (60.0-136.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 21 | 25.8 | 81.4 | (50.4-124.5) |
| Female | 5 | 7.0 | 71.2 | (22.9-166.0) |  | Female | 20 | 11.9 | 167.8 | (102.5-259.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 60 | 56.4 | 106.4 | (81.2-137.0) |  |  |  |  |  |  |
| Female | 45 | 55.5 | 81.0 | (59.1-108.4) |  | Female | 13 | 18.8 | 69.2 | (36.8-118.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 13.3 | 67.7 | (30.9-128.5) |  | Male | 23 | 19.5 | 117.9 | (74.7-176.9) |
| Female | 2 | 3.9 | nc | (nc-nc) |  | Female | 16 | 20.5 | 77.9 | (44.5-126.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 6 | 4.9 | 123.3 | (45.0-268.3) |  | Male | 111 | 156.5 | 70.9 | (58.4-85.4) |
| Female | 10 | 3.7 | 267.7 | (128.2-492.3) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 35 | 31.4 | 111.4 | (77.6-154.9) |  | Male | 20 | 12.5 | 160.3 | (97.9-247.5) |
| Female | 24 | 17.5 | 136.9 | (87.7-203.7) |  | Female | 11 | 7.9 | 139.5 | (69.6-249.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 7.8 | 77.1 | (28.2-167.8) |  | Male | 7 | 10.2 | 68.4 | (27.4-141.0) |
| Female | 5 | 2.5 | 203.5 | (65.6-474.9) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 26 | 22.0 | 118.1 | (77.1-173.0) |  | Male | 10 | 15.5 | 64.5 | (30.9-118.6) |
| Female | 17 | 16.0 | 106.3 | (61.9-170.1) |  | Female | 53 | 40.5 | 130.8 | (98.0-171.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 24 | 18.8 | 127.8 | (81.8-190.1) |  |  |  |  |  |  |
| Female | 7 | 6.6 | 106.5 | (42.7-219.5) |  | Female | 37 | 49.7 | 74.4 | (52.4-102.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 136 | 91.8 | 148.2 | (124.3-175.3) |  | Male | 659 | 682.7 | 96.5 | (89.3-104.2) |
| Female | 141 | 104.3 | 135.1 | (113.7-159.4) |  | Female | 734 | 733.4 | 100.1 | (93.0-107.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

257

# Richmond

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 3.3 | nc | (nc-nc) |  | Male | 0 | 1.9 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 7 | 10.1 | 69.6 | (27.9-143.5) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 12 | 9.9 | 121.2 | (62.6-211.7) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 2.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 5.8 | nc | (nc-nc) |  | Male | 19 | 39.6 | 48.0 | (28.9-75.0) |
| Female | 0 | 5.2 | nc | (nc-nc) |  | Female | 17 | 34.1 | 49.9 | (29.0-79.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

258

# Rochester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 6.0 | 83.3 | (26.9-194.4) |  | Male | 3 | 4.0 | nc | (nc-nc) |
| Female | 3 | 1.8 | nc | (nc-nc) |  | Female | 0 | 2.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 26 | 23.3 | 111.5 | (72.8-163.4) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 3.2 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 6.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 10 | 5.5 | 182.7 | (87.4-335.9) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 26 | 20.7 | 125.4 | (81.9-183.8) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 3.8 | 156.4 | (57.1-340.4) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 3 | 4.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 4 | 5.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 9 | 11.0 | 81.8 | (37.3-155.4) |  | Male | 81 | 81.8 | 99.1 | (78.7-123.1) |
| Female | 6 | 9.3 | 64.2 | (23.4-139.8) |  | Female | 73 | 74.6 | 97.9 | (76.7-123.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

259

# Rockland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 26 | 18.5 | 140.3 | (91.6-205.6) |  | Male | 16 | 12.0 | 132.8 | (75.9-215.7) |
| Female | 9 | 7.2 | 124.8 | (57.0-236.9) |  | Female | 14 | 9.8 | 142.2 | (77.7-238.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 3.7 | 162.5 | (59.3-353.7) |  | Male | 4 | 3.9 | nc | (nc-nc) |
| Female | 4 | 3.2 | nc | (nc-nc) |  | Female | 1 | 3.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 10 | 10.8 | 93.0 | (44.5-171.0) |
| Female | 82 | 80.8 | 101.5 | (80.8-126.0) |  | Female | 18 | 9.8 | 183.2 | (108.5-289.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 9.0 | 122.1 | (60.9-218.5) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 5 | 4.4 | 113.8 | (36.7-265.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 26 | 19.6 | 132.6 | (86.6-194.3) |  |  |  |  |  |  |
| Female | 25 | 20.1 | 124.4 | (80.5-183.7) |  | Female | 7 | 6.9 | 101.0 | (40.4-208.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 4.8 | 208.7 | (99.9-383.9) |  | Male | 6 | 6.9 | 86.7 | (31.6-188.7) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 11 | 7.5 | 146.6 | (73.1-262.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 60 | 57.8 | 103.8 | (79.2-133.6) |
| Female | 2 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 11.0 | 155.2 | (90.3-248.5) |  | Male | 4 | 4.4 | nc | (nc-nc) |
| Female | 15 | 6.5 | 231.0 | (129.2-381.0) |  | Female | 7 | 2.8 | 248.6 | (99.6-512.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 2.8 | nc | (nc-nc) |  | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 7.5 | 119.4 | (54.5-226.7) |  | Male | 3 | 5.0 | nc | (nc-nc) |
| Female | 8 | 5.7 | 139.6 | (60.1-275.2) |  | Female | 17 | 14.2 | 119.7 | (69.7-191.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 6.7 | 74.5 | (24.0-173.9) |  |  |  |  |  |  |
| Female | 4 | 2.4 | nc | (nc-nc) |  | Female | 23 | 18.8 | 122.2 | (77.4-183.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 32 | 32.8 | 97.5 | (66.6-137.6) |  | Male | 276 | 241.3 | 114.4 | (101.3-128.7) |
| Female | 50 | 38.7 | 129.3 | (96.0-170.5) |  | Female | 330 | 269.5 | 122.4 | (109.6-136.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

260

# Rockport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 12.3 | 113.4 | (62.0-190.4) |  | Male | 5 | 7.4 | 68.0 | (21.9-158.7) |
| Female | 2 | 5.0 | nc | (nc-nc) |  | Female | 7 | 5.8 | 120.5 | (48.3-248.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 3 | 1.8 | nc | (nc-nc) |  | Female | 3 | 2.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 3 | 6.4 | nc | (nc-nc) |
| Female | 50 | 47.9 | 104.3 | (77.4-137.5) |  | Female | 4 | 6.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 5.3 | 93.8 | (30.2-218.8) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 5 | 2.8 | 181.0 | (58.3-422.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 11.9 | 75.6 | (34.5-143.5) |  |  |  |  |  |  |
| Female | 6 | 13.6 | 44.2 | (16.1-96.2) |  | Female | 5 | 4.2 | 119.5 | (38.5-278.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 3.1 | nc | (nc-nc) |  | Male | 2 | 4.4 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 3 | 5.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 39 | 37.1 | 105.2 | (74.8-143.8) |
| Female | 2 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 6.5 | 154.0 | (73.7-283.3) |  | Male | 0 | 2.8 | nc | (nc-nc) |
| Female | 5 | 4.0 | 124.7 | (40.2-291.0) |  | Female | 0 | 1.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 4.5 | 134.0 | (48.9-291.7) |  | Male | 0 | 2.4 | nc | (nc-nc) |
| Female | 4 | 3.7 | nc | (nc-nc) |  | Female | 5 | 6.8 | 73.9 | (23.8-172.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 4.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 8 | 11.2 | 71.3 | (30.7-140.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 21.7 | 92.0 | (56.2-142.2) |  | Male | 137 | 149.4 | 91.7 | (77.0-108.4) |
| Female | 14 | 26.0 | 53.8 | (29.4-90.3) |  | Female | 143 | 167.9 | 85.2 | (71.8-100.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

261

# Rowe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 2.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 5 | 9.4 | 53.4 | (17.2-124.6) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 2 | 8.9 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

262

# Rowley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 6.7 | 89.2 | (32.6-194.1) |  | Male | 6 | 4.6 | 131.1 | (47.9-285.3) |
| Female | 6 | 2.4 | 252.4 | (92.2-549.4) |  | Female | 7 | 3.6 | 196.3 | (78.7-404.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 5 | 4.0 | 126.1 | (40.6-294.2) |
| Female | 31 | 28.5 | 108.8 | (73.9-154.4) |  | Female | 4 | 3.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 3.6 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 7.4 | 108.6 | (46.7-213.9) |  |  |  |  |  |  |
| Female | 7 | 7.1 | 97.9 | (39.2-201.8) |  | Female | 4 | 2.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 4 | 2.6 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 3 | 2.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 20 | 22.8 | 87.7 | (53.6-135.5) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 4.3 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 2.8 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 6 | 5.6 | 107.9 | (39.4-234.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 4 | 6.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 12.4 | 80.8 | (38.7-148.7) |  | Male | 81 | 91.6 | 88.4 | (70.2-109.9) |
| Female | 7 | 12.4 | 56.5 | (22.6-116.3) |  | Female | 94 | 93.4 | 100.7 | (81.3-123.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

263

# Royalston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 7 | 6.2 | 112.0 | (44.9-230.8) |  | Female | 2 | 0.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 1.7 | 295.1 | (95.1-688.6) |  |  |  |  |  |  |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 10 | 5.3 | 189.2 | (90.6-347.9) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  | Male | 27 | 20.8 | 129.9 | (85.6-189.0) |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 17 | 19.8 | 85.9 | (50.0-137.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

264